# Solstice Capital

> Solstice Capital is a VC fund in Salem backing Software and Biotechnology. See 33 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Salem, United States
- Total investments: 33
- Last investment: Jul 2011
- Lead investor: 6%
- Last updated: Aug 2026
- Website: http://www.solcap.com

Solstice Capital is a VC fund in Salem focused on Software and Biotechnology. Solstice Capital seeks superior venture capital returns for its limited partners through investments in seed- and early-stage companies in the industry areas of alternative energy, education, the environment, life sciences and information technology.Solstice's unique assets give it a distinct advantage: a seasoned management team withover 90 years of experience in both venture investing and operations in high-growth companiesan emphasis on positive impact investingthe appropriate size fund for early-stage companiesgeographic diversificationFrom its inception, Solstice has demonstrated its commitment to provide both capital and expert guidance to assist portfolio companies as they deal with the challenges and opportunities of growth.An early-stage, diversified, positive impact venture fundSolstice is committed to investing 50% of its capital in information technology and 50% in the following socially responsive investment categories:Alternative EnergyThe EnvironmentLife SciencesEducation

## Contacts

5 contacts available for Solstice Capital. Shizune tracks 3 team members at Solstice Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/solstice-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 7 | 21% |
| Biotechnology | 5 | 15% |
| Security | 3 | 9% |
| Health Care | 3 | 9% |
| Manufacturing | 3 | 9% |

43 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 10 | 30% |
| Series A | 6 | 18% |
| Funding Round | 6 | 18% |
| Series C | 5 | 15% |
| Series D | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Harry George | Co-Founder & Managing General Partner | 5 | https://shizune.co/investors/profile/harry-george |
| Frederick B. Bamber | General Partner | 0 | https://shizune.co/investors/profile/frederick-b-bamber |
| Henry Newman | Co-Founder & General Partner | 0 | https://shizune.co/investors/profile/henry-newman |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| HTG Molecular Diagnostics | HTG Molecular Diagnostics is a provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for translational medicine and diagnostic applications. The Company's NGS-adapted chemistry and HTG EdgeSeq technology automate sample processing and can swiftly, reliably, and concurrently profilehundreds or thousands of molecular targets utilizing a very little quantity of biological material, in liquid or solid form. Its products comprise equipment, consumables, and software that work together to form the HTG EdgeSeq platform. The HTG EdgeSeq platform automates the company's menu of HTG EdgeSeq molecular profiling panels, which use genomic sequencing techniques to swiftly provide gene expression data for clients utilizing its streamlined approach. HTG Molecular Diagnostics was established in 1997 by Bruce E. Seligmann in Tucson, Arizona. | $16.2M | Series D | Jul 13, 2011 |  |
| Regenesis Biomedical | Regenesis Biomedical a medical technology company that focuses on developing and marketing noninvasive regenerative medicine products. The company offers Provant Therapy System, a medical device that aids in reduction of pain and swelling of skin and soft tissues following surgery. Its customers include health care facilities and providers thatserve patients being treated by acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home healthcare agencies, and wound care clinics.Regenesis Biomedical was founded in 1996 and is headquartered in Scottsdale, Arizona. | $5.3M | Series C | Jun 06, 2011 |  |
| Lumidigm | Lumidigm Inc. is a biometric company dedicated to enabling convenient, secure, and reliable identification and verification. Lumidigm powered sensors work because they produce high-quality images every time, in all conditions. Everyone is identifiable. Lumidigm provides biometric identity management for civil ID, point-of-sale, time &attendance, physical and logical access, and portable electronic device applications. | $7M | Series C | Jan 29, 2008 |  |
| Arxan Technologies | Arxan, a global trusted leader providing the industry’s most comprehensive application protection solutions, works with organizations looking to protect critical applications that deployed “into the wild.” Arxan currently protects more than one billion application instances across many industries including financial services, mobile payments,healthcare,automotive, gaming, and entertainment. Unlike legacy security providers that relying on perimeter-based barriers to keep bad actors out or that require device management controls, Arxan products protect at the application-level from the inside out. This approach protects the source and binary code to expand the corporate perimeter of trust. Arxan provides a broad range of patented security capabilities such as a dynamic app policy engine, code hardening, obfuscation, white-box cryptography and encryption, and threat analytics. | $13M | Series C | Mar 05, 2007 |  |
| Regenesis Biomedical | Regenesis Biomedical a medical technology company that focuses on developing and marketing noninvasive regenerative medicine products. The company offers Provant Therapy System, a medical device that aids in reduction of pain and swelling of skin and soft tissues following surgery. Its customers include health care facilities and providers thatserve patients being treated by acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home healthcare agencies, and wound care clinics.Regenesis Biomedical was founded in 1996 and is headquartered in Scottsdale, Arizona. |  | Series B | Aug 21, 2006 |  |
| PhotoThera | PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information.Specialtieslaser, medical device, eschemic, stroke,infrared | $30.5M | Series C | Apr 21, 2006 |  |
| E Ink | E Ink Corp. is a supplier of electronic paper display (EPD) technologies. Products made with E Ink's electronic ink are designed to possess a paper-like high contrast appearance, ultra-low power consumption, and a thin, light form. E Ink's technology is tailored for many consumer and industrial applications including handheld devices,watches, clocks, and public information and promotional signs. | $12M |  | Dec 08, 2005 |  |
| Carefx | Carefx's main solution "Fusionfx" helps close information gaps between hospital/IDN CIO and CMIO and healthcare IT departments.Fusionfx is able to help "synthesize disparate data into clinically relevant, user-centric workflows." The solution aims to connect the data points and make itcomprehensive/understandable fo patients, payers, clinicians, and the compliance agencies who seek such information. | $12.3M | Series B | Oct 25, 2005 |  |
| HTG Molecular Diagnostics | HTG Molecular Diagnostics is a provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for translational medicine and diagnostic applications. The Company's NGS-adapted chemistry and HTG EdgeSeq technology automate sample processing and can swiftly, reliably, and concurrently profilehundreds or thousands of molecular targets utilizing a very little quantity of biological material, in liquid or solid form. Its products comprise equipment, consumables, and software that work together to form the HTG EdgeSeq platform. The HTG EdgeSeq platform automates the company's menu of HTG EdgeSeq molecular profiling panels, which use genomic sequencing techniques to swiftly provide gene expression data for clients utilizing its streamlined approach. HTG Molecular Diagnostics was established in 1997 by Bruce E. Seligmann in Tucson, Arizona. | $3.4M | Series B | Oct 19, 2005 |  |
| Lumidigm | Lumidigm Inc. is a biometric company dedicated to enabling convenient, secure, and reliable identification and verification. Lumidigm powered sensors work because they produce high-quality images every time, in all conditions. Everyone is identifiable. Lumidigm provides biometric identity management for civil ID, point-of-sale, time &attendance, physical and logical access, and portable electronic device applications. | $8.1M | Series B | Oct 03, 2005 |  |

10 of 33 investments shown.

## Co-investors
- [Valley Ventures](https://shizune.co/investors/profile/valley-ventures) — VC Fund, 8 deals together
- [Village Ventures](https://shizune.co/investors/profile/village-ventures) — VC Fund, 7 deals together
- [CB Health Ventures](https://shizune.co/investors/profile/cb-health-ventures) — VC Fund, 3 deals together
- [Grayhawk Capital](https://shizune.co/investors/profile/grayhawk-venture-partners) — VC Fund, 3 deals together
- [Highway 12 Ventures](https://shizune.co/investors/profile/highway-12-ventures) — VC Fund, 3 deals together
- [Toppan Printing](https://shizune.co/investors/profile/toppanprinting) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Solstice Capital invest in?

Solstice Capital invests primarily in Software, Biotechnology and Security startups, most often at Series B and Series A stage. Most of the 33 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Solstice Capital?

Public channels for Solstice Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Solstice Capital?

The team at Solstice Capital includes Harry George (Co-Founder & Managing General Partner), Frederick B. Bamber (General Partner) and Henry Newman (Co-Founder & General Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co